AKEBIA THERAPEUTICS, INC. Contractual Obligation, to be Paid, after Year Five
AKEBIA THERAPEUTICS, INC. (AKBA) had Contractual Obligation, to be Paid, after Year Five of $14.67 million as of 2017-09-30, per its 10-Q filed 2017-11-08.
Discontinued › Notes › Commitment and Contingencies › Contractual Obligation, Fiscal Year Maturity
us-gaap:ContractualObligationDueAfterFifthYear · last filed 2017-11-08
- 2017-09-30: Contractual Obligation, to be Paid, after Year Five $14.67M.
- 2017-06-30: Contractual Obligation, to be Paid, after Year Five $14.67M.
- 2017-03-31: Contractual Obligation, to be Paid, after Year Five $14.67M.
- 2016-12-31: Contractual Obligation, to be Paid, after Year Five $14.67M.
| Period end | Contractual Obligation, to be Paid, after Year Five |
|---|---|
| 2017-09-30 | $14.67M 10-Q · filed 2017-11-08 |
| 2017-06-30 | $14.67M 10-Q · filed 2017-08-08 |
| 2017-03-31 | $14.67M 10-Q · filed 2017-05-09 |
| 2016-12-31 | $14.67M 10-K · filed 2017-03-06 |
| 2016-09-30 | $17.79M 10-Q · filed 2016-11-09 |
| 2016-06-30 | $17.66M 10-Q · filed 2016-08-08 |
| 2016-03-31 | $17.68M 10-Q · filed 2016-05-05 |
| 2015-12-31 | $17.69M 10-K · filed 2016-03-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Greenwich LifeSciences, Inc. (GLSI) | United States | $0.267B | -15.02 |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Mereo BioPharma Group plc (MREO) | $0.269B | -9.41 | |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |